Patent · US Active

Dry powder formulation comprising a phosphodiesterase inhibitor

US9132121B2 · kind B2 · utility

3Cited by

0References

22Claims

0Family size

Assignee

Chiesi Farmaceutici S.p.A. · IT

Inventors

Daniela Cocconi · Parma, IT
Francesca Schiaretti · Parma, IT
Roberto Bilzi · Parma, IT

Key dates

Filing date	Aug 2, 2011
Grant date	Sep 15, 2015
Priority date	—
Expiry date	Aug 2, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Pharmaceutical formulations in the form of inhalable dry powder comprising particles of a phosphodiesterase-4 inhibitor as active ingredient are useful for the prevention and/or treatment of respiratory diseases, such as asthma and COPD.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.